PIK3CA and triple-negative breast carcinoma: Promising preclinical data generated from studies combining RTK and PI3K inhibitors indicate that antitumour responses to PI3K inhibition can be significantly enhanced in triple negative breast cancer models through the combination with a dual EGFR/HER3 antagonist in vitro and in vivo, with important implications for this relatively hard to treat subtype [64].